Pramipexole Combination Therapy to Mitigate GI Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for depression, including pramipexole, often require high doses to achieve efficacy but are limited by significant adverse effects, particularly gastrointestinal issues, making them unsafe and ineffective for chronic use.
Innovation Solution
Combining pramipexole with a 5HT3-antagonist, such as ondansetron, to mitigate gastrointestinal side effects and allow for higher, safe doses of pramipexole, thereby enhancing its antidepressant efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of pramipexole are administered to achieve antidepressant efficacy, then therapeutic effectiveness is improved, but gastrointestinal adverse effects worsen
Solution Approach 1:
A 5HT3-antagonist is introduced as an intermediary substance to block the gastrointestinal adverse effects of pramipexole. The 5HT3-antagonist specifically antagonizes serotonin receptors in the GI tract, preventing pramipexole-induced gastrointestinal disturbances while allowing higher pramipexole doses to achieve antidepressant efficacy
Solution Approach 2:
The dosage parameters of pramipexole are increased beyond conventional Parkinson's disease treatment levels to achieve antidepressant effects. By changing the dose parameter and combining it with a 5HT3-antagonist, the patent enables administration of higher pramipexole doses (e.g., 4.5-18 mg/day) that would otherwise be limited by gastrointestinal tolerance
2Object-affected harmful factors
If conventional antidepressant doses of pramipexole are used for safety, then adverse effects are reduced, but antidepressant efficacy is insufficient
Solution Approach 1:
The 5HT3-antagonist serves as a protective intermediary that enables dose escalation. By blocking gastrointestinal receptors, it creates a buffer that allows pramipexole doses to be increased to therapeutically effective levels for depression without experiencing the full burden of gastrointestinal side effects
Solution Approach 2:
The patent creates a composite therapeutic regimen combining two substances with different mechanisms: pramipexole (dopamine agonist) for antidepressant efficacy and 5HT3-antagonist for gastrointestinal protection. This composite approach synergistically addresses both efficacy and tolerability requirements
Data Source
AI summary
The application describes a method of reducing emesis caused by a dopamine agonist in a patient with depression who is treated with a dopamine agonist, comprising administering ondansetron in combination with the dopamine agonist.